DLBCL not otherwise specified (NOS) represents a heterogeneous entity in terms of morphological features (e.g., centroblastic, immunoblastic), immunophenotype (e.g., CD5+, double MYC/BCL2 expressor) [92–94] and cytogenetic/molecular categories [95]. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.